Gabapentin Market - By Type (Generic, Branded), Dosage Form (Capsule, Tablet, Oral Solution), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome), Distribution Channel, Global Forecast 2024-2032

Gabapentin Market - By Type (Generic, Branded), Dosage Form (Capsule, Tablet, Oral Solution), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome), Distribution Channel, Global Forecast 2024-2032

Gabapentin Market Size

Gabapentin Market was estimated to be worth of USD 2.1 billion in 2023 and is estimated to expand at 4.9% CAGR from 2024 to 2032, due to the rising incidence of neuropathic pain, the growing off-label utilization of gabapentin, the broadening spectrum of gabapentin's applications, and the increasing recognition of gabapentin as an efficacious choice for pain management drug.
 

Gabapentin is a medication mainly prescribed to treat specific types of neuropathic pain and as an anticonvulsant. It is a member of the gabapentinoids drug class. It works by impacting certain chemicals in the brain and nerves that are involved in the sensation of pain and seizures.
 

COVID-19 Impact

During the pandemic, there were concerns about potential supply chain disruptions and availability of essential medications, including gabapentin. These disruptions impacted the timely availability of gabapentin prescriptions for some patients. At the peak of the pandemic, healthcare systems faced significant closure. Elective procedures were delayed, and access to in-person medical appointments was severely restricted for many people who suffer from epilepsy or neuropathic pain. Some patients faced challenges to receive timely care, including medication adjustments. During the pandemic, people experienced increased levels of stress, anxiety, and effects of social isolation. Some people with epilepsy, may experience an increase in seizure frequency due to the stress and anxiety. The pandemic highlighted the importance of mental health.
 

Gabapentin Market Driving Factors

The rising prevalence of epilepsy worldwide is a significant driver for the industry. Gabapentin is widely used as an antiepileptic drug to treat seizures, and the rising number of people are being diagnosed with epilepsy, contributes to the increasing demand. According to WHO, around 50 million people are affected with epilepsy which makes it the most common neurological disease worldwide. Different forms of neuropathic pain, such as diabetic neuropathy, postherpetic neuralgia (pain after shingles), and peripheral neuropathy can be effectively treated with gabapentin. With the increasing global ageing population incidence of conditions like diabetes is rising, leading to the increasing demand for neuropathic pain management solutions, including gabapentin.
 

Gabapentin Restraining Factors

The gabapentin market restraining factors such as side effects associated with gabapentin, availability of alternative treatments, and increasing misuse of gabapentin. Certain side effects, including dizziness, drowsiness, and gastrointestinal issues are associated with gabapentin. Additionally, with time few patients may develop tolerance to gabapentin, necessitating higher doses for the same level of effectiveness.
 

Gabapentin Market Analysis

Based on type, the gabapentin market is classified into generic and branded. In 2022, the generic segment accounted for highest market share of 79.3%. Generic versions of gabapentin are often more widely available, as multiple manufacturers may produce and distribute them. Generally, the generic medications are more affordable than their branded versions. This cost-effectiveness is particularly important for patients and healthcare systems, as it can lead to significant savings in medication expenses. Due to this the generic gabapentin is valuable option, particularly for long-term treatments like epilepsy and chronic pain management.

Based on dosage form, the gabapentin market is classified into capsule, tablet, and oral solution. Among the dosage forms, the capsule segmentis expected to grow at CAGR of 4.9% by 2032. Compared to tablets the capsules offer greater flexibility in terms of dosage adjustments. It allows the healthcare providers to often prescribe specific capsule strengths and alter the dosage as per the requirements. This offers more precise dosing, particularly when patients require doses that fall between standard tablet strengths.

Gabapentin capsules are designed in such a way that the medication is protected from environmental factors such as moisture, light, and air, which can degrade the effectiveness of the drug. Due to the enhanced stability the medication remains potent throughout its shelf life. Owing to the high prescription rate and widespread availability of gabapentin capsules in 100 mg, 300 mg, and 500 mg dosages.

Based on application, the gabapentin market is segmented into epilepsy, neuropathic pain, restless legs syndrome, and other applications. The epilepsy segment is expected to grow at CAGR of 4.7% by 2032. Gabapentin is classified as an anticonvulsant or antiepileptic medication, specifically designed to assist in the control and prevention of seizures. It functions by modulating the activity of certain neurotransmitters and ion channels in the brain, which minimizes the risk of abnormal electrical activity that leads to seizures.

Based on the distribution channel, the gabapentin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held highest market share of 56.2% and is projected to reach USD 1.8 billion.  Hospitals serve as primary healthcare facilities where patients receive treatments for a wide range of medical conditions, including the management of chronic ailments such as epilepsy and neuropathic pain. Gabapentin is frequently prescribed for these conditions, and hospitals play a crucial role in ensuring that patients receive their prescribed medications while under their care.

Based on the region, the gabapentin market in North America was valued to be USD 786.3 million in 2022. The rising prevalence of epilepsy, neuropathic pain, increasing applications of gabapentin for different medical conditions, presence of key players in the industry, research and development of products are collectively boosting the growth of this market. In addition to this, widespread availability and accessibility and increased adoption of gabapentin in North America is expected to support the expansion of this industry.
 

Gabapentin Market Share

The key players in the gabapentin market are

• Pfizer Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd
• Aurobindo Pharma Ltd.
• Amneal Pharmaceuticals LLC
• Cipla Inc.
• BP Pharmaceuticals Laboratories Company
• Assertio Holdings, Inc.
• Arbor Pharmaceuticals, Inc.
• Zydus Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
   

Gabapentin Industry News

• In February 2023, U.S. FDA approved daily use 300 mg and 600 mg Gabapentin tablets of Zydus Pharmaceuticals, Inc. This approval helped the company to enhance the product portfolio of the company and boost the revenue of this company.
   
• In December 2020, Glenmark Pharmaceuticals received tentative ANDA approvals for 300 mg and 600 mg gabapentin enacarbil extended-release tablets. This approval helped the company to strengthen its product portfolio and enhance its customer base.
   

The gabapentin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Type

• Generic
• Branded

By Dosage Form

• Capsule
• Tablet
• Oral solution

By Application

• Epilepsy
• Neuropathic pain
• Restless legs syndrome
• Other applications

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa